Peter Coggins, president of PerkinElmer life and analytical sciences, said that the agreement will help both firms' customers "in transitioning to cellular screening, to drive fundamental productivity improvements into the drug discovery and development process."
Nick Ecos, vice president and general manager of Invitrogen's drug discovery solutions business, said the company would seek similar co-marketing agreements in the future. "We will continue to pair our technologies with those from industry-leading companies like PerkinElmer in order to capitalize on our integrated strength," Ecos said.
Financial details were not discussed.
PerkinElmer first disclosed its plan to partner in the cell-based assay market at the Society for Biomolecular Screening earlier this month.